Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

844 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Endoscopic hemostasis with a self-assembling peptide gel during endoscopic submucosal dissection and cold-snare polypectomy in the duodenum: Prospective exploratory study (with video).
Seya M, Dohi O, Fukui H, Iwai N, Ochiai T, Mukai H, Yamauchi K, Miyazaki H, Yasuda T, Yoshida T, Ishida T, Doi T, Hirose R, Inoue K, Yoshida N, Uchiyama K, Ishikawa T, Takagi T, Konishi H, Itoh Y. Seya M, et al. Among authors: mukai h. Dig Endosc. 2024 Dec 26. doi: 10.1111/den.14974. Online ahead of print. Dig Endosc. 2024. PMID: 39723583
Real-world incidence of and risk factors for abemaciclib-induced interstitial lung disease in Japan: a nested case-control study of abemaciclib-induced interstitial lung disease (NOSIDE).
Nakayama S, Yoshizawa A, Tsurutani J, Yoshimura K, Aoki G, Iwamoto T, Nagase H, Sugimoto N, Kobayashi K, Izumi S, Kato T, Miyazaki Y, Kurihara Y, Taira N, Aihara T, Kikawa Y, Mukai H. Nakayama S, et al. Among authors: mukai h. Breast Cancer. 2024 Nov 18. doi: 10.1007/s12282-024-01648-5. Online ahead of print. Breast Cancer. 2024. PMID: 39556171
A randomized phase III study evaluating dexamethasone-based mouthwash to prevent chemotherapy-induced stomatitis in patients with breast cancer.
Kuba S, Soutome S, Hagiwara Y, Kikawa Y, Iwamoto T, Sangai T, Harao M, Yamaguchi T, Taji T, Igarashi A, Kajimoto Y, Sakurai N, Yamanouchi K, Watanabe K, Maeda N, Suzuki M, Maeda S, Toh U, Ebata A, Iwakuma N, Matsunuma R, Yamaguchi M, Mukai H; CSPOR-BC. Kuba S, et al. Among authors: mukai h. Jpn J Clin Oncol. 2024 Oct 1:hyae136. doi: 10.1093/jjco/hyae136. Online ahead of print. Jpn J Clin Oncol. 2024. PMID: 39354670
Overall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast Cancer.
Schmid P, Cortes J, Dent R, McArthur H, Pusztai L, Kümmel S, Denkert C, Park YH, Hui R, Harbeck N, Takahashi M, Im SA, Untch M, Fasching PA, Mouret-Reynier MA, Foukakis T, Ferreira M, Cardoso F, Zhou X, Karantza V, Tryfonidis K, Aktan G, O'Shaughnessy J; KEYNOTE-522 Investigators. Schmid P, et al. N Engl J Med. 2024 Nov 28;391(21):1981-1991. doi: 10.1056/NEJMoa2409932. Epub 2024 Sep 15. N Engl J Med. 2024. PMID: 39282906 Clinical Trial.
A phase 3 study (PATHWAY) of palbociclib plus tamoxifen in patients with HR-positive/HER2-negative advanced breast cancer.
Noguchi E, Yamanaka T, Mukai H, Yamamoto N, Chung CF, Lu YS, Chang DY, Sohn J, Kim GM, Lee KH, Lee SC, Iwasa T, Iwata H, Watanabe K, Jung KH, Tanabe Y, Kang SY, Yasojima H, Aogi K, Tokunaga E, Sim SH, Yap YS, Matsumoto K, Tseng LM, Umeyama Y, Sudo K, Kojima Y, Hata T, Kuchiba A, Shibata T, Nakamura K, Fujiwara Y, Tamura K, Yonemori K. Noguchi E, et al. Among authors: mukai h. NPJ Breast Cancer. 2024 Aug 22;10(1):76. doi: 10.1038/s41523-024-00684-w. NPJ Breast Cancer. 2024. PMID: 39174547 Free PMC article.
Synthesis of a novel adapter lipid using Fc-region mediated antibody modification for post-insert preparation of transferrin receptor targeted messenger RNA-loaded lipid nanoparticles.
Kato N, Moriya N, Matsumoto M, Matsuo A, Yoshida M, Hiu T, Matsuo T, Takashima Y, Kamiya M, Mukai H, Kawakami S. Kato N, et al. Among authors: mukai h. Eur J Pharm Biopharm. 2024 Oct;203:114468. doi: 10.1016/j.ejpb.2024.114468. Epub 2024 Aug 22. Eur J Pharm Biopharm. 2024. PMID: 39173936 Free article.
Eribulin versus S-1 as first or second-line chemotherapy to assess health-related quality of life and overall survival in HER2-negative metastatic breast cancer (RESQ study): a non-inferiority, randomised, controlled, open-label, phase 3 trial.
Takahashi M, Kikawa Y, Kashiwabara K, Taira N, Iwatani T, Shimozuma K, Ohtani S, Yoshinami T, Watanabe J, Kashiwaba M, Watanabe KI, Kitada M, Sakaguchi K, Tanabe Y, Aihara T, Mukai H. Takahashi M, et al. Among authors: mukai h. EClinicalMedicine. 2024 Jul 16;74:102715. doi: 10.1016/j.eclinm.2024.102715. eCollection 2024 Aug. EClinicalMedicine. 2024. PMID: 39109189 Free PMC article.
844 results